ArticleCommunications medicine2025
Angiotensin receptor-neprilysin inhibitor treatment in people with chronic obstructive pulmonary disease and heart failure.
Article in Communications medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundWhile renin-angiotensin system inhibitors (RASi) have shown benefits for people with both heart failure (HF) and chronic obstructive pulmonary disease (COPD), limited data exists on the use of angiotensin receptor-neprilysin inhibitors (ARNIs) in this population. This study compares the effectiveness of RASi and ARNIs in people with coexisting COPD and HF.
methodsWe identified individuals who started treatment with either ARNI or RASi since August 1, 2015. We assessed outcomes such as COPD exacerbations, acute respiratory failure, and lower respiratory tract infections (LRTIs) over 30 days to 3 years. Kaplan-Meier survival analysis and Cox regression models were applied to estimate survival probabilities and hazard ratios (HR).
resultsAmong 9,071 ARNI users and 71,836 RASi users, the ARNI group has fewer respiratory complications. The ARNI group has a higher proportion of females compared to the RASi group (38.2% vs. 31.5%). Specifically, ARNI users have a lower incidence of COPD exacerbations (13.1% vs. 18.7%; HR, 0.84), acute respiratory failure (16.2% vs. 22.0%; HR, 0.90), and LRTIs (16.9% vs. 22.9%; HR, 0.91).
conclusionsIn people with both COPD and HF, ARNI treatment is associated with fewer respiratory complications compared to RASi.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.